After one year, people taking a GLP-1 drug had better outcomes than those taking an SGLT-2 drug. Specifically, they were 36% less likely to die from any cause, 12% less likely to be hospitalized, 22% ...
Scientists have uncovered evidence that serotonin, the chemical best known for regulating mood, may also speed the ...
Amram Kahn, MD, shares strategies for reconciling disparate clinical recommendations to optimize medication regimens for ...
Individuals with atrial fibrillation (Afib), or irregular heart rhythm, are at increased risk of stroke, chronic kidney ...
A simple formula developed at VCU two decades ago has become a global standard for liver disease detection, helping millions ...
AI can be very knowledgeable. Doctors can have excellent judgment. But ultimately the patient's own priorities often ...
New guidelines may soon make the disorder known as CKM syndrome a common diagnosis.
Cardiovascular-Kidney-Metabolic (CKM) syndrome links heart disease, kidney disease, obesity, and diabetes. New guidelines ...
Samsung’s health features are growing apace, and will offer insights through wearables and other devices, the company’s ...
A 2026 State-of-the-Art review updates the ABCs of cardiovascular disease prevention to help clinicians apply contemporary risk assessment, lifestyle, pharmacologic, and cardiometabolic strategies in ...
Diastolic dysfunction with ventricular stiffening and diffuse fibrosis underpins HFpEF, with hypertension, T2D, AF, CKD, CAD, and adiposity acting as key mechanistic and management modifiers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results